Antibodies

17 Apr 2018 AntoXa Corporation granted Defence R&D Canada license for novel, plant-made anti-ricin antibody
17 Apr 2018 JHL Biotech's Clinical Trial Application Accepted by China for Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers
17 Apr 2018 Five Prime Presents on Novel B7-H4 Therapeutic Antibody at the 2018 AACR Annual Meeting
17 Apr 2018 Harpoon Therapeutics Launches Immuno-Oncology Pipeline With Compelling Data From Lead Programs at the 2018 American Association for Cancer Research (AACR) Annual Meeting
17 Apr 2018 Opdivo Plus Low-Dose Yervoy Combination Reduces the Risk of Progression or Death by 42% Versus Chemotherapy in First-Line Lung Cancer Patients with High Tumor Mutational Burden (TMB)
17 Apr 2018 Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study
17 Apr 2018 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
17 Apr 2018 In CheckMate -141, Opdivo (nivolumab) Demonstrated Sustained Overall Survival (OS) Advantage over Standard of Care in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
17 Apr 2018 Chugai's HEMLIBRA® Receives Breakthrough Therapy Designation from U.S. FDA for Hemophilia A Without Factor VIII Inhibitors
16 Apr 2018 Bioatla Announces FDA Clearance Of Investigational New Drug Application For CAB-ROR2-ADC Therapeutic
16 Apr 2018 Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research
16 Apr 2018 Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis
16 Apr 2018 BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
16 Apr 2018 Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support
16 Apr 2018 Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting
16 Apr 2018 VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR
16 Apr 2018 Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release
16 Apr 2018 Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma
15 Apr 2018 Seattle Genetics Highlights Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology Program Advances at the American Association for Cancer Research (AACR) Annual Meeting
15 Apr 2018 MabSpace Initiated Global Phase 1 Trial of MSB2311, Its 2nd Generation PD-L1 Antibody With a Distinct Intra-Tumor Recycling Property
15 Apr 2018 Alphamab’s Novel Her-2 Bispecific Antibody KN026 Gains IND Approval in China; CMC Validation of Its Proprietary Bispecific Platform
15 Apr 2018 Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly Chinese Population with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
10 Apr 2018 Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs
10 Apr 2018 BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
09 Apr 2018 KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top